Cognition Therapeutics, Inc.
Cognition Therapeutics, Inc. (CGTX) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · CGTX · as of Jun 9, 2026
Key Statistics
Explore Cognition Therapeutics, Inc. Data
cgtx stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 7 · Buy rate: 85.7%
Competitors & Peers
cgtx competitorsCGTX
AGEN
ATOS
GLSI
IRD
MCRBStock Performance
Full HistoryAbout Cognition Therapeutics, Inc.
Cognition Therapeutics, Inc. is a biopharmaceutical company in the clinical stage, focused on identifying and advancing small molecule treatments. The firm's research and development efforts are prima…
what is cognition therapeutics, inc. · cgtx stock overview · cognition therapeutics, inc. company profile · who is cognition therapeutics, inc. ceo · cgtx NASDAQ · cognition therapeutics, inc. headquarters · cognition therapeutics, inc. business segments
About Stock Overview & Key Data
Cognition Therapeutics, Inc. (CGTX) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Oct 8, 2021. As of the latest trading session, CGTX stock price is $1.21, with a market capitalization of $89.0M. The stock has returned +300.26% over the past 12 months and -10.37% year-to-date.
According to 7 Wall Street analysts, the consensus rating for Cognition Therapeutics, Inc. stock is Buy, with an average 12-month price target of $—. In fiscal year 2025, Cognition Therapeutics, Inc. reported revenue of — and net income of -$23.5M. For detailed data — including Cognition Therapeutics, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Cognition Therapeutics, Inc. (CGTX) stock price is $1.21. The stock is traded on NASDAQ under the ticker symbol CGTX. The 52-week range is $0.25 – $3.83.